192 related articles for article (PubMed ID: 17579472)
21. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
[TBL] [Abstract][Full Text] [Related]
22. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
[TBL] [Abstract][Full Text] [Related]
23. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.
Hoppmann S; Qi S; Miao Z; Liu H; Jiang H; Cutler CS; Bao A; Cheng Z
J Biol Inorg Chem; 2012 Jun; 17(5):709-18. PubMed ID: 22418921
[TBL] [Abstract][Full Text] [Related]
24. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
Mousa SA; Mohamed S; Wexler EJ; Kerr JS
Anticancer Res; 2005; 25(1A):197-206. PubMed ID: 15816539
[TBL] [Abstract][Full Text] [Related]
26. [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
Sundberg AL; Gedda L; Orlova A; Bruskin A; Blomquist E; Carlsson J; Tolmachev V
Cancer Biother Radiopharm; 2004 Apr; 19(2):195-204. PubMed ID: 15186600
[TBL] [Abstract][Full Text] [Related]
27. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
[TBL] [Abstract][Full Text] [Related]
28. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.
Liu S; Hsieh WY; Jiang Y; Kim YS; Sreerama SG; Chen X; Jia B; Wang F
Bioconjug Chem; 2007; 18(2):438-46. PubMed ID: 17341108
[TBL] [Abstract][Full Text] [Related]
30. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis.
Jiang L; Miao Z; Kimura RH; Silverman AP; Ren G; Liu H; Lu H; Cochran JR; Cheng Z
J Biomed Biotechnol; 2012; 2012():368075. PubMed ID: 22570527
[TBL] [Abstract][Full Text] [Related]
31. Selective targeting of E. coli heat-stable enterotoxin analogs to human colon cancer cells.
Giblin MF; Sieckman GL; Watkinson LD; Daibes-Figueroa S; Hoffman TJ; Forte LR; Volkert WA
Anticancer Res; 2006; 26(5A):3243-51. PubMed ID: 17094436
[TBL] [Abstract][Full Text] [Related]
32. Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138.
Mousa SA; Mohamed S
J Cardiovasc Pharmacol; 2005 Feb; 45(2):109-13. PubMed ID: 15654258
[TBL] [Abstract][Full Text] [Related]
33. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
Wang Z; Tian R; Niu G; Ma Y; Lang L; Szajek LP; Kiesewetter DO; Jacobson O; Chen X
Bioconjug Chem; 2018 Sep; 29(9):3213-3221. PubMed ID: 30105912
[TBL] [Abstract][Full Text] [Related]
34. In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone.
Liu D; Overbey D; Watkinson LD; Daibes-Figueroa S; Hoffman TJ; Forte LR; Volkert WA; Giblin MF
Anticancer Res; 2009 Oct; 29(10):3777-83. PubMed ID: 19846908
[TBL] [Abstract][Full Text] [Related]
35. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
36. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
37. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
38. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
Kenanova V; Olafsen T; Williams LE; Ruel NH; Longmate J; Yazaki PJ; Shively JE; Colcher D; Raubitschek AA; Wu AM
Cancer Res; 2007 Jan; 67(2):718-26. PubMed ID: 17234783
[TBL] [Abstract][Full Text] [Related]
39. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
Price EW; Zeglis BM; Cawthray JF; Ramogida CF; Ramos N; Lewis JS; Adam MJ; Orvig C
J Am Chem Soc; 2013 Aug; 135(34):12707-21. PubMed ID: 23901833
[TBL] [Abstract][Full Text] [Related]
40. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation.
Janssen M; Frielink C; Dijkgraaf I; Oyen W; Edwards DS; Liu S; Rajopadhye M; Massuger L; Corstens F; Boerman O
Cancer Biother Radiopharm; 2004 Aug; 19(4):399-404. PubMed ID: 15453954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
